Compare GNE & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GNE | RCEL |
|---|---|---|
| Founded | 2011 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 408.2M | 403.3M |
| IPO Year | 2011 | 2018 |
| Metric | GNE | RCEL |
|---|---|---|
| Price | $16.66 | $15.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $13.46 |
| AVG Volume (30 Days) | 50.1K | ★ 410.9K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.80% | N/A |
| EPS Growth | ★ 95.65 | 27.20 |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $425,202,000.00 | $71,610,000.00 |
| Revenue This Year | N/A | $24.33 |
| Revenue Next Year | $1.86 | $26.85 |
| P/E Ratio | $30.89 | ★ N/A |
| Revenue Growth | N/A | ★ 11.45 |
| 52 Week Low | $12.69 | $3.22 |
| 52 Week High | $17.11 | $16.90 |
| Indicator | GNE | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 51.80 | 66.15 |
| Support Level | $15.80 | $3.86 |
| Resistance Level | $16.89 | N/A |
| Average True Range (ATR) | 0.49 | 0.92 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 54.77 | 75.00 |
Genie Energy Ltd, through its subsidiaries, operates as a retail energy provider. It serves two reportable business segments: Genie retail energy, or GRE, and Genie renewables. The Genie retail energy segment resells energy to residential and commercial consumers in the Eastern and Midwestern United States through its portfolio of various retail energy providers. The Genie renewables segment holds controlling interests in various companies engaged in the manufacturing of solar panels, solar installation design, and solar energy project management. It generates the majority of its revenue from the Genie retail energy segment.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.